ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Neurofibromatosis type 1: a clinical case

Neurofibromatosis type 1: a clinical case

Authors:
Вашкевич А.А.,
Константин Игоревич Разнатовский,
Томашева А.О.,
Дулаев А.К.,
Гвенетадзе В.В.,
Резцова П.А.,
Корнишева В.Г.,
Котрехова Л.П.,
Гулордава М.Д.,
Клибсон С.К.

Журнал: Клиническая дерматология и венерология. 2022;21(6):758-764.

DOI: 10.17116/klinderma202221061758

Read: 7241 раз

Download PDF (RU)

Abstract

Neurofibromatosis, a neurocutaneous syndrome (syndrome with neurologic and cutaneous manifestations), refers to a heterogeneous group of inherited disorders of the tumor growth suppression mechanism characterized by multiple benign and malignant skin and nervous system tumors. This condition has a variety of extracutaneous manifestations: cardiovascular, gastrointestinal, ophthalmologic, orthopedic, etc., and each of them significantly reduces the quality of life and affects the prognosis of the disease. A distinction is made between neurofibromatosis type 1 (formerly known as von Recklinghausen’s disease), neurofibromatosis type 2, and schwannomatosis, which once was considered a variant of neurofibromatosis type 2 but is now considered a distinct type of disease. All types of neurofibromatosis are genetically determined, autosomal dominant disorders, but each variant differs in the spectrum of tumors and the set of mutated genes responsible for specific clinical manifestations. Due to the rarity of this condition, diagnosis is often difficult for practitioners, especially in children. We present a clinical case demonstrating the cutaneous, ophthalmologic, and orthopedic patterns of neurofibromatosis type 1 with the distinctive features of a challenging diagnostic search. A multidisciplinary approach to this condition is necessary.

Keywords

  • neurofibromatosis
  • genetics
  • diagnosis
  • clinic
  • criteria

Дата поступления: 07.02.2022

Дата принятия в печать: 19.09.2022

Дата публикации: 20.12.2022

References
  1. Borofsky S, Levy LM. Neurofibromatosis: Types 1 and 2. American Journal of Neuroradiology. 2013;34(12):2250-2251. https://doi.org/10.3174/ajnr.A3534
  2. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F. 2010. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am J Med Genet. Part A 152A:327-332. https://doi.org/10.1002/ajmg.a.33139
  3. Gareth Evans, Naomi L Bowers, et al. Schwannomatosis: a genetic and epidemiological study, J Neurol Neurosurg Psychiatry. 2018;89(11):1215-1219. https://doi.org/10.1136/jnnp-2018-318538
  4. Germaine L Defendi. Genetics of Neurofibromatosis Type 1 and Type 2. Medscape. 2020, Aug 10.
  5. Friedman JM. Neurofibromatosis 1. 1998, Oct 2. (Updated 2019 Jun 6). In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle. Seattle (WA): University of Washington, Seattle; 1993-2022. https://www.ncbi.nlm.nih.gov/books/NBK1109/#_nf1_References_
  6. Evans DG. Neurofibromatosis 2. Initial Posting: October 14, 1998 ( Last Update: March 15, 2018). Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993-2022. https://www.ncbi.nlm.nih.gov/books/NBK1201/
  7. Evans DG, Baser ME, O’Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19(1):5-12. https://doi.org/10.1080/02688690500081206
  8. DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000; 105(3 Pt 1):608-614. https://doi.org/10.1542/peds.105.3.608
  9. Bruce Korf, Scott R. Plotkin, et al. Cutaneous neurofibromas. Current clinical and pathologic issues. Neurology. 2018;91(2 suppl 1):5-13. https://doi.org/10.1212/WNL.0000000000005792
  10. Pasmant E, Ortonne N, Rittié L, et al. Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis. J Neuropathol Exp Neurol. 2010;69(1):60-69. https://doi.org/10.1097/NEN.0b013e3181c79bff
  11. David T Hsieh. Neurofibromatosis Type 1 Clinical Presentation. Medscape. Apr 23, 2020.
  12. Hivelin M, Wolkenstein P, Lepage C, et al. Facial aesthetic unit remodeling procedure for neurofibromatosis type 1 hemifacial hypertrophy: report on 33 consecutive adult patients. Plast Reconstr Surg. 2010;125(4):1197-1207. https://doi.org/10.1097/PRS.0b013e3181d180e9
  13. Listernick R, Ferner RE, Liu, GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann Neurol. 2007;61(3):189-198. https://doi.org/10.1002/ana.21107
  14. Diggs-Andrews KA, Brown JA, Gianino SM, et al. Sex is a major determinant of neuronal dysfunction in neurofibromatosis type1. Ann Neurol. 2014; 75(2):309-316. https://doi.org/10.1002/ana.24093
  15. Andrew A Dahl. Ophthalmologic Manifestations of Neurofibromatosis Type 1 (NF-1). Medscape. Jul 15, 2021.
  16. Gómez Moyano E, Martínez Pilar L, Rodriguez Calvo de Mora M, et al. Using dermoscopy to assess diagnostic criteria of neurofibromatosis. J Am Acad Dermatol. 2015;73(1):e17-18. https://doi.org/10.1016/j.jaad.2015.03.053
  17. Crawford AH, Schorry EK. Neurofibromatosis in children: the role of the orthopaedist. J Am Acad Orthop Surg. 1999;7(4):217-230. https://doi.org/10.5435/00124635-199907000-00002
  18. Wozniak W, Karwacki MW. Is «watchful waiting» superior to surgery in children with neurofibromatosis type 1 presenting with extracranial and extramedullary tumor mass at diagnosis? Childs Nerv Syst. 2008;24(12): 1431-1436.
  19. Seop Park Y. Spinal deformity in neurofibromatosis: Classification and management. J Spine. 2014;3:1-5. https://doi.org/10.4172/2165-7939.1000186
  20. Yoshida Y, Ehara Y, Koga M, Imafuku S, Yamamoto O. Epidemiological analysis of major complications requiring medical intervention in patients with neurofibromatosis 1. Acta Derm Venereol. 2018;98:753-756. https://doi.org/10.1111/1346-8138.13902
  21. Feldman DS, Jordan C, Fonseca L. Orthopaedic manifestations of neurofibromatosis type 1. J Am Acad Orthop Surg. 2010;18:346-357. https://doi.org/10.5435/00124635-201006000-00007
  22. Le C, Bedocs PM. Neurofibromatosis. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK459329/
  23. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51-57.
  24. Shah KN. The diagnostic and clinical significance of café-au-lait macules. Pediatr Clin North Am. 2010;57:1131-1153. https://doi.org/10.1016/j.pcl.2010.07.002
  25. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best. JAMA. 2002;287(11):1427-1434. https://doi.org/10.1001/jama.287.11.1427
  26. Karagiannis A, Mikhailidis DP, Athyros VG & Harsoulis F 2007 Pheochromocytoma: an update on genetics and management. Endocrine-Related Cancer. 14;935-956. https://doi.org/10.1677/ERC-07-0142
  27. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92-102. https://doi.org/10.1038/ncpendmet0396
  28. Prada CE, Hufnagel RB, Hummel TR, et al. The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr. 2015;167:851-856. https://doi.org/10.1016/j.jpeds.2015.07.001
slide-cover
slide-cover
slide-cover

Recommended articles:

Healthy young adults with a family history of alcohol dependence: Suicidal ideation, anxiety, and «novelty-seeking».S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(8):96-103

Mechanisms and morpho-pathophysiological levels of epileptogenesis.S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(8):5-12

Awareness of primary care physicians regarding the diagnosis and treatment of rheumatoid arthritis in the Chelyabinsk region.Russian Journal of Preventive Medicine. 2026;29(7):25-30

Surgeon’s tactics in appendiceal mucocele.Russian Journal of Operative Surgery and Clinical Anatomy. 2026;10(2-2):103-108

Clinical case of diagnosis and treatment of extranasopharyngeal angiofibroma.Russian Bulletin of Otorhinolaryngology. 2026;91(3):111-114

Infectious urethritis in men: etiology, epidemiology, diagnosis and treatment (analytical review).Russian Journal of Clinical Dermatology and Venereology. 2026;25(3):464-472

Problems of diagnosis and treatment of mycosis fungoides in children.Russian Journal of Clinical Dermatology and Venereology. 2026;25(3):450-457

Dyshormonogenetic goiter in a patient with congenital hypothyroidism: clinical, morphological and genetic features.Russian Journal of Archive of Pathology. 2026;88(3):59-65

Congenital intrathoracic accessory spleen: a case report.Pirogov Russian Journal of Surgery. 2026;(6):108-112

Subjective cognitive impairment in patients with cerebral microangiopathy.S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(5):63-73

Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29
  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12
  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru
  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026